09/30/2026
🎗️🐾New Osteosarcoma Clinical Trial for Dogs
UPenn VetMed is enrolling dogs newly diagnosed with osteosarcoma for a fully funded clinical trial using advanced CAR‑iNKT immune cell therapy. All diagnostics, amputation, and chemo are covered.
If your dog has a new OSA diagnosis, this could be an important option.
Help move canine cancer research forward!
In this study we will investigate the therapeutic potential of immune cells known as invariant natural killer T (iNKT) cells made from the blood of a healthy donor dog, to treat dogs with bone cancer. iNKT cells are potent immune cells that have been shown to kill cancer cells in mouse models